This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Five Dumbest Things on Wall Street This Week: Oct. 12

2. J&J Meets G&G

We got a chuckle over Johnson & Johnson's (JNJ - Get Report) troubles this week courtesy of our friends over at Goldman & Goldman (GS).

No, that's not a typo. We doubled-up on Goldman for a reason. Allow us to explain.

The investment bank's research analyst Jami Rubin downgraded the drug giant to sell from neutral Tuesday based on her belief that the company's focus on getting bigger is causing it to become less competitive. Shares of Johnny John, as Wall Street traders call it, sank 1.5% to $68 on the news.

"In our view, JNJ's focus on M&A versus cash returns to shareholders or a break-up strategy (like PFE, ABT, COV, BAX) puts it at a disadvantage as other companies get more aggressive. We advocated a creative strategy in our May 30 note, The case for breaking up J&J, which we believe would unlock significant value that is currently trapped in JNJ's conglomerate structure. However, our sense is that management has low interest in this approach to capital allocation," wrote Rubin.

Alright, she's entitled to her opinion, and it certainly is a candid one considering we rarely see bulge bracket investment banks telling clients to dump Dow components, and especially established ones like J&J. But that's not what tickled our funny bone though.

No, what amused us about this particular sell call is where J&J's management got the bright idea to bulk up in the first place. Guess who planted the seed in J&J's mind to get bigger? Come on, give it a shot.

Yep, Goldman Sachs itself. As pointed out by TheStreet's very own Antoine Gara in his Street Whispers column Tuesday, Rubin's bearish outlook on J&J -- predicated on a misguided M&A strategy -- comes only a few months after Goldman's investment bankers helped seal the healthcare giant's largest-ever acquisition.

"The real surprise is how arguments floated by Goldman's research analysts appear to undercut the bank's front and center role as an advisor to J&J on its $19.7 billion acquisition of medical device maker Synthes, the largest deal in the company's 126-year history. The downgrade is especially noteworthy given that Goldman's advisory work for J&J was also likely considered to be a capstone 2012 success in a relatively weak year for dealmakers," wrote Gara.

Look, we appreciate that Goldman's research arm is finally showing its independence after all the troubles it heaped on itself during the tech bubble (the last one that is). It really is refreshing to see a conflict of interest within an investment bank, as opposed to one between an investment bank and its client.

That said, you gotta admit the whole thing is laughable. And it will be even more so when J&J eventually takes Rubin's advice and breaks itself up. You just know they will. And guess who will pocket the advisory fees when they decide to get smaller?

Come on, give it a shot.
4 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GE $30.63 0.00%
JNJ $112.69 0.00%
TSRA $31.00 0.00%
UBS $15.91 0.00%
WFC $50.00 0.00%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs